OneSource Specialty Pharma (ONESOURCE) investor relations material

Executive summary

• Q1 FY27 revenue reached INR 4,490 million (Rs. 4,490.23 million), up 37% year-over-year, driven by semaglutide launches in Canada and India, new contracts, and biologics momentum.

• EBITDA rose to INR 1,233 million ($13.1m), a 39% year-over-year and 34% sequential increase, reflecting strong operational performance and margin expansion.

• Consolidated profit after tax for Q1 FY27 was Rs. 249.97 million, a turnaround from a loss in Q1 FY26.

• Significant progress in semaglutide commercialization, with over 40% of India's generic pens market supplied from the company's site and multiple G7 approvals.

• Added new customers, expanded capacity with a second cartridge line set for commercialization in Q2, and signed a strategic biosimilars partnership.

Financial highlights

• Revenue grew 37% year-over-year to INR 4,490 million ($47.5m), up 5% sequentially.

• EBITDA increased 39% year-over-year to INR 1,233 million ($13.1m), with margins expanding to 27.5%.

• Adjusted PAT was $6.7m, up 63% QoQ and 72% YoY; reported PAT turned positive from a loss in Q1FY26.

• Standalone EPS for Q1 FY27 was Rs. 4.47, and consolidated EPS was Rs. 2.18, both up significantly year-over-year.

• Margin improvement driven by higher contribution from drug device combination business.

Outlook and guidance

• FY 2028 guidance reaffirmed: INR 400 million ($400m) organic revenue and 40% EBITDA margin, with ROCE above 50%.

• Strong order book visibility and capacity expansion support confidence in achieving FY 2028 targets.

• Growth expected to continue beyond FY 2028, with biologics, drug device, and soft gelatin businesses as key drivers.

• Europe and U.S. markets expected to open up from FY 2029/2030, further boosting growth.

• The Board and auditors expressed confidence in the Group’s financial reporting and compliance.